Results 121 to 130 of about 13,126 (223)

Adverse events associated with use of immunoglobulin in pediatric patients reported to the US Food and Drug Administration Adverse Event Reporting System, 2001-2023. [PDF]

Pediatr Allergy Immunol
Wei S, Kim Y, Rubin MN, Ayyala SS, Welsh K.   +4 more
europepmc   +1 more source

Postmarketing safety surveillance for GSK's AS01_E-adjuvanted respiratory syncytial virus prefusion F protein-based vaccine in the USA: protocol for a non-interventional postauthorisation safety study. [PDF]

BMJ Open
Adimadhyam S, Luyts D, Oraichi D, Deraedt Q, Pircon JY, Bilker WB, Agan AA, Rajbhandari R, Carbonari DM, Djibo DA, Wang X, Nolan MB, DeVries A, Selvan M, Ma Q, Wentz AE, Daniels K, Platt R, Lo Re V, Cocoros NM.   +19 more
europepmc   +1 more source

Controversial efficacy of antithrombin followed by recombinant thrombomodulin administration in patients with sepsis-induced disseminated intravascular coagulation: an analysis of postmarketing surveillance data. [PDF]

Thromb J
Eguchi Y, Nagafuchi H, Ikeda T.
europepmc   +1 more source

After the green light: Evaluating drugs in Phase IV studies.

Indian J Pharmacol
Meher BR, Mishra A.
europepmc   +1 more source

GLP-1 receptor agonists and functional gastrointestinal obstruction: mechanistic rationale, emerging evidence, and clinical implications. [PDF]

Ann Med Surg (Lond)
Riaz L, Ajmal A, Siddiquei H, Memon U, Jaber Amin JH.   +4 more
europepmc   +1 more source

The Value of A Postmarket Knowledge Exchange [PDF]

Biomedical Instrumentation & Technology, 2015
openaire   +2 more sources

Postmarket Safety Actions for Novel Oncology Drugs Granted FDA's Accelerated Approval.

JAMA Netw Open
Mooghali M, Wallach JD, Mitchell AP, Ross JS, Ramachandran R.   +4 more
europepmc   +1 more source

Policy Without Penalty: A Review of Pediatric Research Equity Act Noncompliance Letters. [PDF]

Pediatrics
Green DJ, Pagano A, Goldman J, Deshmukh AD.   +3 more
europepmc   +1 more source

Navigating hepatotoxicity of antibody-drug conjugates: from mechanistic insights to clinical and postmarketing evidence. [PDF]

Front Pharmacol
Dong Y, Zhi Y, Li X, Ma M, Ye M, Huang S, Tang J, Zhong W, Lei X, Mao Y.   +9 more
europepmc   +1 more source

Unanticipated Adverse Events With Tirzepatide: Three Cases Underscoring the Importance of Postmarketing Monitoring. [PDF]

JCEM Case Rep
Colorado M, Gomez Miranda J, Arias-Morales CE.   +2 more
europepmc   +1 more source